xCures Unveils Next-Generation AI-Powered Data Platform at HLTH Conference

The platform leverages AI to deliver real-time insights that will significantly reduce the time and effort needed to make informed clinical decisions.

xCures Connects as a Qualified Health Information Network (QHIN) Participant

xCures, a leader in healthcare technology, proudly announces its successful activation as a Qualified Health Information Network (QHIN) participant.

Expanded Access Program for gallium maltolate (GaM) Now Open

Investigational cancer treatment with the potential to slow brain tumor growth is now available for patients with relapsed/refractory glioblastoma.

Clarified Precision Medicine and xCures Form Strategic Partnership to Transform Patient Outcomes Through Precision Oncology

Collaboration will focus on analyzing and improving guidelines-based utilization of precision medicine to better support oncologists and cancer patients.

Kidney Cancer Association enters strategic partnership with xCures

The partnership will empower patients with greater control over their health data and accelerate the discovery and approval of new treatments for kidney cancer.

xCures to showcase the value of its healthcare data platform at the 2024 ASCO Annual Meeting

xCures' patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers.

xCures Announces Issuance of Groundbreaking Patent

USPTO awards patent for AI tech enabling virtual trials, enhancing clinical decisions through continuous learning from patient experiences.

xCures Unveils Expanded AI Health Data Platform: Now Supporting All Therapeutic Areas and is Available as SaaS

The company’s platform expansion transforms the value of US healthcare data by harnessing real-time, regulatory-grade data in any therapeutic area to efficiently understand the complex medical histories of patients and drive research through detailed, longitudinal datasets.

xCures and Aetion® Further Enhance Partnership with Rich Real-World Datasets

Partnership now includes access to five comprehensive oncology datasets, enhancing real-world evidence in cancer research.

xCures to offer clinical data extraction as a service in AWS Marketplace

AWS cloud configurations will help xCures customers to leverage the company’s robust data gathering and structuring services while maintaining secure, private ownership of their data.

xCures Partners with the Pancreatic Cancer Action Network (PanCAN)

xCures offers unparalleled access to data and the xINFORM patient portal to accelerate pancreatic cancer research and improve patient care OAKLAND, CA - xCures, a leader in real-time clinical data technology, is thrilled to announce a pivotal partnership with the Pancreatic Cancer Action Network (PanCAN).

xCures Platform advances progress on the White House Cancer Moonshot mission to end cancer as we know it.

New study will collect, organize, and share data for Diffuse Midline Glioma (DMG) and Diffuse Intrinsic Pontine Glioma (DIPG) research.

xUTILITY to Lead the Way Integrating Research and Patient Care

Seamless integration with existing healthcare infrastructures drives unprecedented possibilities to improve medical research and patient care.

xCures to Contribute Data to Support Aetion®’s Collaboration with FDA

xCures data deemed fit-for-purpose to address research questions relevant to the prevention, clinical care, diagnostics, and treatment in oncology.

xCures and DDRFA partner to make an impact on patient-driven DIPG & DMG research

xCures’ technology harnesses real-time patient data and makes it accessible for scientific exploration and to improve patient options.

CureMatch and xCures Partner to Revolutionize the Standard for Precision Cancer Treatment Processes

CureMatch will leverage the xCures technology that automatically creates a comprehensive outline of a cancer patient’s medical history in order to improve treatment recommendations.

xCures showcases the power of its real-time clinical data platform at ASCO Annual Meeting 2023

Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations.

Genome Medical and xCures Partner to Enhance Genetic Services with Personalized Clinical Data

Genome Medical and xCures have joined forces to provide patients with a new level of personalized care.

xCures partners with RenovoRx to assist patients in accessing RenovoRx’s TIGeR-PaC study

RenovoRx's Phase III clinical study is open to pancreatic adenocarcinoma patients and focuses on extending overall survival and improving quality of life.

xCures Joins Big Names in Aetion’s New Initiative

xCures, a Real-Time Regulatory Grade Clinical Data (RRC) platform, will be joining Aetion, a global real-world evidence software and analytics provider, and a group of leading diverse partners in Aetion’s launch of the Coalition for the Advancement of RWE through Randomized Controlled Trial Emulation (CARE) Initiative.

xCures presents clinical and translational research with two posters at the 2022 SNO Annual Meeting

XCELSIOR registry showcases its power in using real-world datasets and clinical outcomes to aid decision-making and treatment options for CNS cancer patients.

Finally, cancer patients have real-time access to their medical records

Recent changes to patients’ data rights enable xCures’ platform to automatically retrieve patient medical records from institutions and generate powerful care summaries.

xCures and mProbe partner to help cancer patients determine optimal treatments

xCures partners with mProbe, to leverage their targeted proteomics platform for profiling individual patients' cancer tissues for actionable drug targets xCures, Inc.

xCures and Oblato announce the launch of a Compassionate Use program for OKN-007

Oblato’s first-in-class small molecular OKN-007 will be available through a newly opened compassionate use protocol.

Pancreatic Cancer Patients Will Now Have Remote Access to Precision Nutrition Trial Through New Partnership

xCures and Vault Health integration creates a decentralized platform to benefit pancreatic cancer research and facilitate enrollment in Faeth’s NEAAR-001 study xCures, Inc.

xCures partners with Travera to support advanced carcinoma patients and their physicians 

Decentralized clinical trial for patients with advanced carcinomas helps determine their cancer’s response to specific drugs [EIN Presswire, July 19, 2022] xCures, Inc.

xCures and Novocure® partner to better understand quality of life in glioblastoma

Innovative collaboration focused on developing the first comprehensive Quality of Life dataset for glioblastoma patients [EIN PressWire June 21, 2022] xCures, Inc.

Prognos Health and xCures Partner to enable Access to Real World Oncology Datasets

The new collaboration focuses on improving outcomes by continuous learning from every patient’s journey across diverse datasets CHICAGO, IL, UNITED STATES, June 3, 2022 /EINPresswire/  Today, at the annual meeting of the American Society of Clinical Oncology (ASCO), Prognos Health and xCures announced a collaboration to enable real-world data access and insights for life science companies across multiple use cases.

xCures joins C-Path’s Cure Drug Repurposing Collaboratory to Deliver AI-enabled Data Abstraction of Health Records

Members of CDRC will be able to utilize xCures’ technology to quickly abstract and structure clinical data to support drug repurposing studies in rare cancer.

Endeavor BioMedicines Partners with xCures to Identify Patients with PTCH1 mutations for Phase 2 Trial of ENV-101 (taladegib)

xCures to use tumor sequencing information and its platform to pair patients with available treatment options Endeavor BioMedicines, a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, and xCures, a company that aims to improve cancer outcomes and accelerate cancer research using artificial intelligence, today announced a partnership that gives patients enrolling in Endeavor's clinical trials access to the xCures platform to find the best available treatment options suited to their individual tumor profile.

xCures announces real world biomarker study for patients with FGFR-mutant bladder cancer receiving Balversa®

Tyra Biosciences supported study investigates if non-invasive blood and urine samples provide biomarkers to assess clinical response to erdafitinib treatment Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy.

xCures and BioSpark partner to boost Real World Oncology Data offerings

New partnership allows for a 40,000+ patient dataset to unlock new insights into cancer treatments and outcomes.

TARGET: Cancer Podcast to be hosted by media personality Dr. Sanjay Juneja – TheOncDoc

Oncologist and cancer educator Dr.

xCures Webinar: Implications of new FDA draft guidance on real-world data explained

TORONTO (PRWEB) DECEMBER 01, 2021 The FDA has issued two new draft guidance documents on the use and structure of real-world data in regulatory decision-making.

xCures presents the results of their oncology platform at the 2021 SNO Annual Meeting

xCures’ poster at the SNO meeting will show results from their XCELSIOR platform of real-world datasets and clinical outcomes in CNS cancer patients.

xCures hosts xDECIDE webinars

xCures is inviting the oncology community to register for a 25-minute webinar introducing a new clinical decision support tool: xDECIDE.

xCures launches xDECIDE to help oncologists find better treatment options for their patients

Portal helps oncologists find the most recent and relevant therapeutic options for advanced cancer patients so they can focus on treatment evaluation xCures announced today the release of xDECIDE, the latest in the company's suite of tools to empower oncologists and their teams to identify the most suitable, personalized treatment options for advanced cancer patients more efficiently.

Jaime Leandro Foundation treats first cancer patient with personalized neoantigen peptide vaccine under expanded access through xCures

First-of-its-kind consortium enables cancer patients to receive anticancer vaccine therapy through compassionate use.

xCures raises $12.69 million in Series A funding for their AI-powered precision oncology platform

xCures has helped 1000+ advanced cancer patients and their oncologists with treatment options and recently enabled direct access to the platform through xINFORM Oakland, June 23rd, 2021 (PRNewswire) - xCures Inc.

xCures provides early access to xINFORM

Today, xCures enabled early access to xINFORM, an A.

xCures partners with FibroFighters to launch a real-time learning platform for Fibrolamellar Hepatocellular Carcinoma

Collection and analysis of real-time data about Fibrolamellar aim to deliver essential information for doctors and patients about this rare form of liver cancer Today, xCures announced their collaboration with the FibroFighters Foundation to launch a real-time learning platform for the Fibrolamellar Hepatocellular Carcinoma (FLHCC) community.

xCures partners with CureScience to make leading translational research available to advanced cancer patients

Doctors and patients will benefit from the integration of xCures’ patient-oriented tracking infrastructure and CureScience's precision medicine tools Today, xCures announced its partnership with CureScienceTM so that patients across the US can have access to leading translational science approaches through a decentralized clinical research platform.

xCures launches xACCESS for Providers

A.

xCures announces collaboration with CancerCompass to better support patients and caregivers through their cancer journey

Today, xCures announced their collaboration with CancerCompass, allowing consumers who contact CancerCompass to access the xCures' platform and services.

xCures Joins Decentralized Trials & Research Alliance (DTRA) to Democratize and Accelerate Clinical Trials

New Global Industry Coalition Aims to Dramatically Increase Access for All Patients Populations in Clinical Trials and Research December 23, 2020 – xCures joins a historic alliance of fifty life sciences and healthcare organizations that seeks to accelerate the broad adoption of patient-focused, decentralized clinical trials and research.

xCures launches xACCESS – A new module in their AI-assisted clinical platform

The new registration module facilitates expanded access to novel therapies for patients with advanced cancer while accelerating the generation of real-world data on safety and efficacy.

xCures announces the launch of a Compassionate Use program for ulixertinib (BVD-523)

BioMed Valley Discoveries’ first-in-class ERK inhibitor available through newly opened compassionate use protocol.

xCures together with Cancer Commons and a confidential partner, to launch a virtual medical food trial in patients with pancreatic cancer

San Francisco, CA, September 23, 2020.

BEAT19 crowd-sourcing study jump starts data collection for research to find effective treatments in battle against COVID-19

– 240 million Americans can play a vital role in the search for a vaccine or treatment by contributing critical data from home – SAN FRANCISCO – April 15, 2020 – xCures, a health technology company focused on the use of artificial intelligence, has released preliminary data from the company’s Behavior, Environment, And Treatments for COVID-19 (BEAT19) registry study, NCT04321811.

Oncology Pioneer xCures Names Experts to Advisory Boards

Prominence of Scientific and company Advisory Board signals attraction to xCures’ novel patient-centric approach to treatment and continuous learning for cancer LOS ALTOS, CA, USA, October 10, 2019 -- Today, xCures Inc.

Integrating Clinical Research And Care In A Perpetual Trial

With attention focused on the difficulties associated with traditional oncologic clinical trials, xCures’ Perpetual Trial and the potential for a Real World Data-based learning ecosystem has gained attention.

Oncology Expert Keith T. Flaherty, MD Named Chairman of xCures Scientific Advisory Board

Keith T.

xCures to Implement an Intermediate Size Expanded Access Protocol for ONC201 in H3 K27M-Mutant Gliomas

LOS ALTOS, Calif.

Upcoming Events

Las Vegas, NV
San Diego, CA
Nashville, TN
Nashville, TN
Nashville, TN
Miami Beach, FL